ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mosunetuzumab

Also written as “Mosunetuzumab”, “Mosunetuzumab (IV)” and “Mosunetuzumab (SC)”.

Its studies are mostly in Lymphoma, Follicular · Lymphoma, B-Cell · Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Non-Hodgkin · Lupus Nephritis, led by 2 companies.

Drug pageMosunetuzumab: every studyAll 47 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jan 13, 202114 company-led studies, 7 open or runningNext primary completion: Jul 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only137 open or runningphase 3since Jan 13, 2021Jul 14, 2015Jul 31, 2027phase 2 · NCT05207670
Ipsen10 open or runningphase 2since Dec 29, 2021Dec 29, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Ipsen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2017Named mosunetuzumabINNProposed as its International Nonproprietary Name in WHO's List 117
  2. Dec 29, 2021First study: phase 2 study in Hematologic NeoplasmsFirst studyNCT05205252 · United States

TargetBeta

CD3E →MS4A1 →read by rule
“T cell surface glycoprotein CD3 binding agent; B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
glofitamabruleHoffmann-La Rochephase 313
epcoritamabruleGenmabphase 313
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492AstraZenecaphase 22
GSK5926371GlaxoSmithKlinephase 22
REGN9220ruleRegeneron Pharmaceuticalsphase 21
Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543ruleJohnson & Johnsonphase 13

Studies

The one study Ipsen leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05205252Hematologic Neoplasms · United States2WithdrawnJul 5, 20230

How it is read

Names in the registry

  • “Mosunetuzumab”, 8 entries
  • “Mosunetuzumab (IV)”, 2 entries
  • “Mosunetuzumab (SC)”, 2 entries
  • “Mosunetuzumab (Cohorts A-C)”, 1 entry
  • “Mosunetuzumab (Cohorts D-E)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.